hookipa
pharma
present
svb
leerink
cyberx
series
vaccine
forum
new
york
vienna
austria
globe
newswire
hookipa
pharma
nasdaq
hook
hookipa
company
developing
new
class
immunotherapeutics
targeting
infectious
diseases
cancers
based
proprietary
arenavirus
platform
today
announced
hookipa
management
team
participate
present
svb
leerink
cyberx
series
vaccine
forum
taking
place
september
hookipa
fireside
chat
wednesday
september
pm
et
joern
aldag
ceo
igor
matushansky
cmo
hookipa
hookipa
pharma
nasdaq
hook
clinical
stage
biopharmaceutical
company
developing
new
class
immunotherapeutics
targeting
infectious
diseases
cancers
based
proprietary
arenavirus
platform
reprograms
body
immune
system
hookipa
proprietary
technologies
replicating
induce
robust
cells
antibodies
hookipa
viral
vectors
target
antigen
presenting
cells
vivo
activate
immune
system
technologies
enable
repeat
administration
augment
refresh
immune
responses
monotherapy
replicating
arenavirus
technology
potential
induce
cell
response
levels
previously
achieved
approaches
hookipa
prophylactic
cytomegalovirus
cmv
vaccine
candidate
currently
phase
clinical
trial
patients
awaiting
kidney
transplantation
expand
infectious
disease
portfolio
hookipa
entered
collaboration
licensing
agreement
gilead
sciences
research
functional
cures
hiv
chronic
hepatitis
b
infections
addition
hookipa
building
proprietary
pipeline
targeting
virally
mediated
cancer
antigens
antigens
lead
replicating
arenavirus
oncology
product
candidates
development
treatment
human
papilloma
virus
cancers
phase
clinical
trial
initiated
december
ind
application
cleared
fda
june
find
hookipa
online
information
please
contact
